Search research articles

Search research articles

Related Experiment Videos

Cardiac allograft vasculopathy.

Lana Renae Rhodes¹

¹Methodist Specialty and Transplant Hospital, San Antonio, TX 78229, USA. lanaboomersooner@sbcglobal.net

Critical Care Nursing Quarterly

|February 21, 2004

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same journal

The Relationship Between Ethical Ideology and Moral Resilience in Critical Care Nurses.

Critical care nursing quarterly·2026

Same journal

The Effect of Monitor Alarm Management Training on the Level of Alarm Fatigue of Nurses in Intensive Care Units.

Critical care nursing quarterly·2026

Same journal

Oral Care in Patients With Invasive Airway Management in the ICU: A Prospective Observational Study.

Critical care nursing quarterly·2026

Same journal

Nurses' Perceived Barriers to the Implementation and Sustainability of Best Patient Safety in Handover in the Clinical Setting: Cross-Sectional Survey Study.

Critical care nursing quarterly·2026

Same journal

Association Between Early Tracheostomy and Patient Outcomes in Critically Ill Patients on Mechanical Ventilator: A Retrospective Cohort Study.

Critical care nursing quarterly·2026

Same journal

Nurses' Knowledge of Blood Transfusion Safety at Intensive Care Units in Jordan: A Cross-Sectional Study.

Critical care nursing quarterly·2026

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Cardiac allograft vasculopathy (CAV) is a major cause of death after heart transplantation. This accelerated coronary artery disease in recipients currently has retransplantation as its only definitive treatment.

Area of Science:

Cardiology
Transplantation Medicine
Immunology

Background:

Heart transplantation is a standard treatment for end-stage heart disease.
Cardiac allograft vasculopathy (CAV) is a significant complication, leading to death in over half of heart transplant recipients within a year.
CAV is characterized by accelerated obliterative coronary artery disease in the transplanted heart.

Purpose of the Study:

To review the pathogenesis, characteristics, and treatment options for cardiac allograft vasculopathy (CAV) in heart transplant recipients.
To highlight the challenges associated with managing CAV and its impact on long-term transplant outcomes.

Main Methods:

Literature review of pathogenesis, clinical characteristics, and treatment modalities for CAV.
Discussion of current therapeutic strategies and future directions.

Related Experiment Videos

Main Results:

CAV represents an accelerated form of coronary artery disease unique to heart transplant recipients.
Retransplantation is currently the only definitive treatment for CAV.
Significant obstacles, including ethical considerations and donor organ scarcity, limit the feasibility of retransplantation.

Conclusions:

CAV remains the primary cause of late mortality following heart transplantation.
Effective management strategies for CAV are urgently needed to improve long-term survival and outcomes for heart transplant recipients.
Addressing the challenges of retransplantation is crucial for improving the prognosis of patients with CAV.